Breaking News, Collaborations & Alliances

Enteris to Develop Orally Delivered Metabolic Peptide

Enters agreement with Nordic Bioscience to lead the formulation and clinical manufacturing of Peptelligence-enabled compounds

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enteris BioPharma, a biotechnology company developing drug products built around its proprietary delivery technologies, has formed a clinical manufacturing services agreement with KeyBioscience AG, a wholly-owned subsidiary of Nordic Bioscience. Enteris will use its proprietary Peptelligence platform to advance the development of a proprietary metabolic peptide for the treatment of various indications, including diabetes, obesity, and other metabolic disorders. Enteris BioPharma will leverage...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters